Device Trial Radar · NCT07211126
The Real-World Control-IQ Glycemic Control and Quality of Life Study in Type 1 Diabetes in France
Last checked: Nov 19, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
350
Planned (sponsor's estimate)
Start
Mar 3, 2026
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Tandem Diabetes Care, Inc.Public (TNDM)
- Sponsor type
- Industry
- First posted
- Oct 7, 2025
Design
- Study type
- Observational
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 6 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This post-market surveillance study is primarily designed to demonstrate the ongoing safety of the Control-IQ system, the ongoing performance of glycemic control and quality of life with Control-IQ system use, and the rate of use of the Control-IQ system. The system will be assessed in all approved populations during the first 12 months of use.
Conditions
- Diabetes Mellitus, Type 1
Interventions
t:slim X2 insulin pump with Control-IQ technology (Control-IQ System)Device
Participants enrolled in the study will start use of the t:slim X2 insulin pump with Control-IQ technology (Control-IQ System) with Dexcom G6 or Dexcom G7, and be followed for 12 months.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of diabetic ketoacidosis (DKA).Time frame: 12 months
- Rate of severe hypoglycemia (SH)Time frame: 12 months
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
CH Agen-Nérac
Agen, France · Recruiting
CHU d'Angers
Angers, France · Recruiting
CHU Lyon HFME
Bron, France · Recruiting
22 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.